Ginkgo Bioworks 3Q22 Digest
Update on the Short Thesis
Disclaimer: The calculations herein have not been reviewed by anyone and some of them are just high level approximations. Please don’t rely on this information for your investment decisions. I am not providing financial advice with this newsletter. This is simply me trying to figure out this company and inviting you to join me in this journey. Feedback is always welcome in case you have comments, questions or additional context.
Fallacy Alarm is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
On November 14, 2022, DNA 0.00%↑ reported their 3Q22 earnings. In this article, I will contextualize their results in terms of my overall view on the stock and where I see the fair value at this point. I had done something similar as a Twitter thread after 2Q22:
Ginkgo Bioworks was founded in 2009 by MIT scientists based on the mission to find industrial applications for the genetic engineering of microbes. I have written about them in my Amyris articles, most notably here:
Revenue cycle in full swing
I have explained the Ginkgo revenue cycle in detail in the article above. Just giving a short summary here to refresh your memory:
Keep reading with a 7-day free trial
Subscribe to Fallacy Alarm to keep reading this post and get 7 days of free access to the full post archives.